Skip to content

A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products

Diabetic Macular Edema | Central Retinal Vein Occlusion | Neovascular Age-Related Macular...

The VOYAGER study is a primary data collection, non-interventional, prospective, multinational, multicenter study. It is designed to collect real-world, long-term data to explore long-term effectiveness, safety, clinical insights, treatment patterns, and factors driving the treatment decisions among patients being treated with specified Roche ophthalmology products in approved retinal indications (Faricimab for neovascular age-related macular degeneration \[nAMD\], diabetic macular edema \[DME\], and retinal vein occlusion; Port Delivery System with Ranibizumab for nAMD) in routine clinical practice. This study will not provide or make recommendations on use of any products including Roche products; treatment decisions will be determined by the treating physician and must be made independently to the decision to participate in this study. Participation in this study will not change or influence a patient's standard of care in any way.

null

Conditions de participation

  • Sexe:

    ALL
  • Âges admissibles:

    18 and up

Critères de participation

Inclusion Criteria:

1. Have provided informed consent, as required per local regulations 2.a) Adult patient, as defined by local regulations and local product label, who is newly initiating treatment (or initiated treatment in the previous visit) with a specified approved Roche ophthalmology product in retinal indication of interest for this study in at least one eye, according to the investigator's discretion in routine clinical practice; OR 2.b) Adult patient, as defined by local regulations and local product label, who is continuing treatment with any specified approved Roche ophthalmology product in retinal indication of interest for this study in at least one eye after initiating that treatment in a Roche interventional trial.

Exclusion Criteria:

1. Concomitant participation of the patient in an investigational ophthalmology clinical trial that includes receipt of any investigational drug or procedure within the last 28 days prior to enrollment (this restriction does not apply to patients who are rolling over from Roche interventional studies and continuing treatment with any specified approved Roche ophthalmology product in retinal indication of interest for this study)

Lieu de l'étude

St. Joseph's Health Care - London
St. Joseph's Health Care - London
London, Ontario
Canada

Contactez l'équipe d'étude

Institut De L'Oeil Des Laurentides
Institut De L'Oeil Des Laurentides
Boisbriand, Quebec
Canada

Contactez l'équipe d'étude

St Joseph's Centre for Mountain Health Services
St Joseph's Centre for Mountain Health Services
Hamilton, Ontario
Canada

Contactez l'équipe d'étude

Clarity eye Institute
Clarity eye Institute
Vaughan, Ontario
Canada

Contactez l'équipe d'étude

Retina MD Clinic
Retina MD Clinic
Sainte-catherine, Quebec
Canada

Contactez l'équipe d'étude

The Retina Centre of Ottawa
The Retina Centre of Ottawa
Ottawa, Ontario
Canada

Contactez l'équipe d'étude

Universite de Montreal - Hopital Maisonneuve-Rosemont (HMR) - Centre Ambulatoire
Universite de Montreal - Hopital Maisonneuve-Rosemont (HMR) - Centre Ambulatoire
Montreal, Quebec
Canada

Contactez l'équipe d'étude

Retina Surgical Associates
Retina Surgical Associates
New Westminster, British Columbia
Canada

Contactez l'équipe d'étude

Toronto Retina Institute
Toronto Retina Institute
Toronto, Ontario
Canada

Contactez l'équipe d'étude

Eye Health MD (Opthalmology)
Eye Health MD (Opthalmology)
Montreal, Quebec
Canada

Contactez l'équipe d'étude

Étude parrainée par
Hoffmann-La Roche
Participants recherchés
Plus d'informations
ID de l'étude: NCT05476926